SAN DIEGO, PARSIPPANY, N.J. and INDIANAPOLIS, July 12 /PRNewswire/ — Accumetrics, Inc.,
Daiichi Sankyo, Inc, and Eli Lilly and Company announced today that
the companies have entered into a strategic collaboration in the United States to raise awareness
about antiplatelet therapy and the role of platelet function
testing.
Several factors, including a patient’s genetic make-up, diabetic
status, age, weight and the use of certain other medications
metabolized through the cytochrome P450 pathway in the body may
influence patient response to antiplatelet medicines.
Therefore, it is important that physicians understand their
options to determine if their use of a specific antiplatelet
medicine is having its intended effect.
Antiplatelet medicines help prevent blood platelets from
sticking or clumping together, reducing the likelihood that
arteries will be blocked by a clot, leading to a heart attack.
The focus of the collaboration is to educate healthcare
professionals about the availability and reliability of a rapid and
easy-to-use platelet function test, and to stress the importance of
assessing each patient’s platelet response to antiplatelet
medications.
“By working closely with Daiichi Sankyo and Lilly, we hope to
offer greater understanding of platelet function testing as a means
to help physicians assess patients’ platelet response to
antiplatelet therapy,” said Timothy I.
Still, President and CEO of Accumetrics.
“We believe physicians will want to know the specific effect of
a patient’s antiplatelet therapy and whether additional measures
may be needed,” said
SOURCE
